Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
161,353
archived clinical trials in
Cancer

Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
The Cancer Center of Hawaii-Pali Momi
mi
from
'Aiea, HI
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
The Cancer Center of Hawaii-Pali Momi
mi
from
'Aiea, HI
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Baptist Memorial Hospital and Cancer Center-Desoto
mi
from
Southhaven, MS
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Baptist Memorial Hospital and Cancer Center-Desoto
mi
from
Southhaven, MS
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
FirstHealth of the Carolinas-Moore Regional Hospital
mi
from
Pinehurst, NC
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
FirstHealth of the Carolinas-Moore Regional Hospital
mi
from
Pinehurst, NC
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Baptist Memorial Hospital and Cancer Center-Collierville
mi
from
Collierville, TN
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Baptist Memorial Hospital and Cancer Center-Collierville
mi
from
Collierville, TN
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
McFarland Clinic PC - Ames
mi
from
Ames, IA
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
McFarland Clinic PC - Ames
mi
from
Ames, IA
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Central Care Cancer Center - Great Bend
mi
from
Great Bend, KA
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Central Care Cancer Center - Great Bend
mi
from
Great Bend, KA
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Lakeland Hospital Niles
mi
from
Niles, MI
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Lakeland Hospital Niles
mi
from
Niles, MI
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Lakeland Medical Center Saint Joseph
mi
from
Saint Joseph, MI
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Capital Region Southwest Campus
mi
from
Jefferson City, MO
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Capital Region Southwest Campus
mi
from
Jefferson City, MO
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Vidant Oncology-Kinston
mi
from
Kinston, NC
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Vidant Oncology-Kinston
mi
from
Kinston, NC
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Cancer Care Specialists of Illinois - Decatur
mi
from
Decatur, IL
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Southwest Illinois Health Services LLP
mi
from
Swansea, IL
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Southwest Illinois Health Services LLP
mi
from
Swansea, IL
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Sanford Joe Lueken Cancer Center
mi
from
Bemidji, MN
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Sanford Joe Lueken Cancer Center
mi
from
Bemidji, MN
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Audie L. Murphy VA Hospital
mi
from
San Antonio, TX
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Audie L. Murphy VA Hospital
mi
from
San Antonio, TX
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Dayton Physician LLC-Miami Valley Hospital North
mi
from
Dayton, OH
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Dayton Physician LLC-Miami Valley Hospital North
mi
from
Dayton, OH
Click here to add this to my saved trials
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated:  12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Veliparib With or Without Radiation Therapy, Carboplatin, and Paclitaxel in Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed by Surgery
A Dose Finding Study Followed by Phase II Randomized, Placebo-Controlled Study of Veliparib (ABT-888) Added to Chemoradiotherapy With Carboplatin and Paclitaxel for Unresectable Stage III Non-small Cell Lung Cancer (NSCLC), (NCI Study Number 8811)
Status: Enrolling
Updated: 12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma
Phase II Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Stage III-IV Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma
Phase II Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Stage III-IV Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 12/31/1969
Sanford Roger Maris Cancer Center
mi
from
Fargo, ND
Click here to add this to my saved trials
Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma
Phase II Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Stage III-IV Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated:  12/31/1969
Sanford Hematology and Oncology
mi
from
Sioux Falls, SD
Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Head and Neck Carcinoma
Phase II Study of DCA (Dichloroacetate) in Combination With Cisplatin and Definitive Radiation in Stage III-IV Squamous Cell Carcinoma of the Head and Neck
Status: Enrolling
Updated: 12/31/1969
Sanford Hematology and Oncology
mi
from
Sioux Falls, SD
Click here to add this to my saved trials
Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy
A Pilot Study to Determine the Efficacy of Cryoablation for the Treatment of Invasive Breast Carcinoma Following Neoadjuvant Therapy
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Cryoablation for Invasive Breast Carcinoma Following Neoadjuvant Therapy
A Pilot Study to Determine the Efficacy of Cryoablation for the Treatment of Invasive Breast Carcinoma Following Neoadjuvant Therapy
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer
End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer
End of Life Treatment Preferences of Latino Medicare Beneficiaries With Cancer
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
Vaccination of High Risk Breast Cancer Patients
Phase 1 Safety Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDE ISA 51 VG Adjuvant
Status: Enrolling
Updated:  12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Vaccination of High Risk Breast Cancer Patients
Phase 1 Safety Study of a Carbohydrate Mimotope Based Vaccine With MONTANIDE ISA 51 VG Adjuvant
Status: Enrolling
Updated: 12/31/1969
University of Arkansas for Medical Sciences
mi
from
Little Rock, AR
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
UCLA Hematology/Oncology Clinic
mi
from
Los Angeles, CA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
UCLA Hematology/Oncology Clinic
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Moffitt Cancer Center
mi
from
Tampa, FL
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
University of Chicago
mi
from
Chicago, IL
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
University of Chicago
mi
from
Chicago, IL
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Massachusetts General Hospital Cancer Center
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Carolina BioOncology Institute
mi
from
Huntersville, NC
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Hospital of the University of Pennsylvania Abramson Cancer Center
mi
from
Philadelphia, PA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Hospital of the University of Pennsylvania Abramson Cancer Center
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Sarah Cannon Research Institute
mi
from
Nashville, TN
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Yale Cancer Center
mi
from
New Haven, CT
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Norton Cancer Institute
mi
from
Louisville, KY
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
University of Maryland
mi
from
Baltimore, MD
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
University of Maryland
mi
from
Baltimore, MD
Click here to add this to my saved trials
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated:  12/31/1969
Neely Center for Clinical Cancer Research, Tufts Medical Center
mi
from
Boston, MA
Safety Study of MGA271 in Refractory Cancer
A Phase 1 Dose Escalation Study of MGA271 in Refractory Cancer
Status: Enrolling
Updated: 12/31/1969
Neely Center for Clinical Cancer Research, Tufts Medical Center
mi
from
Boston, MA
Click here to add this to my saved trials
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated:  12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma (RCC)
A Randomized Phase 2 Trial of Pazopanib Versus Temsirolimus in Poor-Risk Clear-Cell Renal Cell Carcinoma
Status: Enrolling
Updated: 12/31/1969
University of Texas M.D. Anderson Cancer Center
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
Boston, MA
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
Boston, MA
Click here to add this to my saved trials
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer
Status: Enrolling
Updated:  12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
A Phase 1 Study of LY2835219 In Participants With Advanced Cancer
A Phase 1 Study of a CDK 4/6 Dual Inhibitor in Participants With Advanced Cancer
Status: Enrolling
Updated: 12/31/1969
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer
Status: Enrolling
Updated:  12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
PET/CT in Diagnosing Patients With Liver Cancer Undergoing Surgical Resection
Genomic and Imaging Study for Patients Undergoing Surgery for Liver Cancer
Status: Enrolling
Updated: 12/31/1969
University of Hawaii Cancer Center
mi
from
Honolulu, HI
Click here to add this to my saved trials
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
Phase I/II Pilot Study of Lapatinib in Combination With Carboplatin and Paclitaxel in the Treatment of Recurrent/Metastatic Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ)
Status: Enrolling
Updated:  12/31/1969
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
Phase I/II Pilot Study of Lapatinib in Combination With Carboplatin and Paclitaxel in the Treatment of Recurrent/Metastatic Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ)
Status: Enrolling
Updated: 12/31/1969
University Hospitals Seidman Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
Phase I/II Pilot Study of Lapatinib in Combination With Carboplatin and Paclitaxel in the Treatment of Recurrent/Metastatic Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ)
Status: Enrolling
Updated:  12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Lapatinib With Carboplatin and Paclitaxel in Esophagus and Gastroesophageal Junction (GEJ)
Phase I/II Pilot Study of Lapatinib in Combination With Carboplatin and Paclitaxel in the Treatment of Recurrent/Metastatic Adenocarcinoma of the Esophagus and Gastroesophageal Junction (GEJ)
Status: Enrolling
Updated: 12/31/1969
Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
mi
from
Cleveland, OH
Click here to add this to my saved trials
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status: Enrolling
Updated:  12/31/1969
Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles
mi
from
Los Angeles, CA
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status: Enrolling
Updated: 12/31/1969
Children's Center for Cancer and Blood Diseases, Children's Hospital Los Angeles
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status: Enrolling
Updated:  12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status: Enrolling
Updated: 12/31/1969
Children's Hospital Boston
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status: Enrolling
Updated:  12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status: Enrolling
Updated: 12/31/1969
Dana-Farber Cancer Institute
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status: Enrolling
Updated:  12/31/1969
Fakultni nemocnice Brno
mi
from
Brno,
A Study of Sunitinib In Young Patients With Advanced Gastrointestinal Stromal Tumor
A PHASE I/II STUDY OF SUNITINIB IN YOUNG PATIENTS WITH ADVANCED GASTROINTESTINAL STROMAL TUMOR
Status: Enrolling
Updated: 12/31/1969
Fakultni nemocnice Brno
mi
from
Brno,
Click here to add this to my saved trials
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
University of Alabama at Birmingham
mi
from
Birmingham, AL
Click here to add this to my saved trials
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
Radiological Associates of Sacramento
mi
from
Sacramento, CA
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
Radiological Associates of Sacramento
mi
from
Sacramento, CA
Click here to add this to my saved trials
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
New York University Langone Medical Center
mi
from
New York, NY
Click here to add this to my saved trials
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated:  12/31/1969
Cancer Treatment Centers of America (CTCA)
mi
from
Tulsa, OK
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Evaluating an Anchored Transponder in Lung Cancer Patients Receiving Radiation Therapy
Status: Enrolling
Updated: 12/31/1969
Cancer Treatment Centers of America (CTCA)
mi
from
Tulsa, OK
Click here to add this to my saved trials